Periprocedural myocardial injury (MI) is common after transcatheter aortic valve implantation (TAVI), but valve type may not influence its occurrence. Data presented at the European Society of Cardiology (ESC) 2025 show comparable MI incidence and one-year outcomes across transcatheter heart valve (THV) platforms.

In a cohort of 898 adults with severe aortic stenosis undergoing transfemoral TAVI between 2021 and 2023, 353 received balloon-expandable valves (BEV) and 545 received self-expanding valves (SEV). Patients treated with BEV were younger (mean 79.7 vs 83.2 years; P=0.001) and had lower preoperative risk scores. Postprocedural high-sensitivity cardiac troponin I (hs-cTnI) levels were slightly higher in SEV patients (297.0 ng/L vs 263.0 ng/L; P=0.083) but not significantly different.

MI rates did not differ between groups using various criteria: 4th Universal Definition of Myocardial Infarction (62.4% vs 56.1%; P=0.07), Society for Cardiovascular Angiography and Interventions (7.7% vs 5.9%; P=0.38), and Academic Research Consortium-2 (1.8% vs 2.3%; P=0.84). One-year all-cause mortality was also similar (hazard ratio for SEV 0.81, 95% confidence interval 0.51–1.29; P=0.38).

These findings indicate that both THV platforms provide comparable periprocedural safety and long-term outcomes in severe aortic stenosis treated with TAVI.